



MEDICAL TIPS

DIABIZ TABLETS

Issue I, No.1, 2024

Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Ostrominski JW, et al. Circulation. 2023; 148(24): 1945-1957

- Treatment-resistant hypertension (TRH - defined as BP $\geq 140/90$ mm Hg despite treatment with 3 antihypertensive drugs including a diuretic) is associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction (HFrEF/HFpEF).
- In this sub-analysis of the DELIVER trial (n=6263), potential role of Dapagliflozin among patients with TRH (n=718) was evaluated.
- Participants with TRH exhibited the greatest reduction in the rate of primary events (cardiovascular death or worsening HF) with Dapagliflozin (4.1 per 100 patient-years)
- Dapagliflozin reduced systolic BP (by ≈ 1 to 3 mm Hg) without increasing risk of hypotension, hypovolemia, or other serious adverse events, irrespective of BP category.

Dapagliflozin consistently improved clinical outcomes and was well-tolerated, including among those with TRH.

